DÄ internationalArchive4/2008Essential Thrombocythemia – Clinical Significance, Diagnosis and Treatment: Tyrosine Kinase Mutation

Correspondence

Essential Thrombocythemia – Clinical Significance, Diagnosis and Treatment: Tyrosine Kinase Mutation

Dtsch Arztebl Int 2008; 105(4): 71. DOI: 10.3238/arztebl.2008.0071b

Stern, S

LNSLNS Although you explain the JAK2V617F tyrosine kinase mutation in your very good article, you do not mention at all the possibility of tyrosine kinase inhibition, as seen for example with imatinib administration in CML. Are there really no new therapeutic strategies for essential thrombocythemia in this area? DOI: 10.3238/arztebl.2008.0071b

Dr. med. Stefan Stern
AOK Bayern – Die Gesundheitskasse
DLZ KH/Reha Oberpfalz/Niederbayern
Schäfflerstr. 5, 93309 Kelheim, Germany
stefan.stern@by.aok.de

Info

Specialities